Aprea Therapeutics, Inc. (APRE): Shareholders' Equity
$12.44M
As of 2025-12-31
$38.47M
As of 2026-06-30
-21.4%
3-year compound annual growth
-30.6%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.44M | -35.6% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $19.31M | +13.9% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $16.95M | -33.9% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $25.64M | -48.2% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $49.51M | -36.0% | 2024-03-26, Balance as of period end |
| 2020-12-31 | $77.40M | -37.7% | 2023-03-30, Balance as of period end |
| 2019-12-31 | $124.24M | n/m | 2022-03-15, Balance as of period end |
| 2018-12-31 | -$51.44M | n/m | 2021-03-16, Balance as of period end |
| 2017-12-31 | -$35.77M | n/a | 2020-03-27, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | $12.44M | -35.6% |
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | $8.65M | +964.2% |
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | $15.16M | -24.2% |
| Synlogic, Inc. (SYBX) | 2025-12-31 | $11.86M | -7.0% |
| Aditxt, Inc. (ADTX) | 2025-12-31 | $5.61M | +235.0% |
| Cingulate Inc. (CING) | 2025-12-31 | $2.51M | -66.3% |
| Tempest Therapeutics, Inc. (TPST) | 2025-12-31 | $6.67M | -65.1% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $8.54M | -40.3% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $14.48M | -31.1% |
Compare APRE, RVPH, ANIX, SYBX side by side · Screen every company in Pharmaceutical Preparations ↗